Panbela Therapeutics, Inc. is conducting trials from pre-clinical to Phase III registration programs. Late-stage programs are orphan oncology related: pancreatic cancer and FAP (familial adenomatous polyposis). In pancreatic cancer, the ASPIRE trial, a Global Randomized Double-Blind Placebo Controlled Trial of SBP-101 with gemcitabine and nab-paclitaxel in patients previously untreated for metastatic pancreatic ductal adenocarcinoma is open with a target of 60-80 sites. The FAP Phase III Registration trial is a partnered program anticipated to begin in the first half of 2023.